MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

Strona główna・Stock List・Relay Therapeutics Inc

Relay Therapeutics Inc

Open

SectorHealthcare

7.08 -0.98

Buy Sell

Overview

Share price change

24h

Current

Min

6.78

Max

7.14

Key metrics
By Trading Economics
Income	6.7M -70M
Sales	-7M 677K
Profit margin	-10,395.126
Employees	197
EBITDA	8M -77M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+111.25% upside

Market Stats
By TradingEconomics
Market Cap	496M 1.1B
Previous open	8.06
Previous close	7.08

News Sentiment

By Acuity

50%

160 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

2.88 / 3.285 Support & Resistance

Relay Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 paź 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20 paź 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

20 paź 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20 paź 2025, 22:14 UTC

Market Talk

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20 paź 2025, 22:00 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20 paź 2025, 21:49 UTC

Acquisitions, Mergers, Takeovers

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20 paź 2025, 20:56 UTC

Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 paź 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 paź 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

20 paź 2025, 20:38 UTC

Earnings

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20 paź 2025, 20:38 UTC

Earnings

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20 paź 2025, 20:38 UTC

Earnings

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20 paź 2025, 20:36 UTC

Earnings

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20 paź 2025, 20:36 UTC

Earnings

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20 paź 2025, 20:36 UTC

Earnings

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20 paź 2025, 20:36 UTC

Earnings

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20 paź 2025, 20:16 UTC

Market Talk

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20 paź 2025, 20:05 UTC

Earnings

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20 paź 2025, 19:39 UTC

Earnings

Acquisitions, Mergers, Takeovers

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20 paź 2025, 19:34 UTC

Market Talk

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20 paź 2025, 19:32 UTC

Market Talk

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20 paź 2025, 19:00 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 paź 2025, 18:29 UTC

Market Talk

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20 paź 2025, 18:11 UTC

Market Talk

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20 paź 2025, 18:04 UTC

Market Talk

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20 paź 2025, 17:03 UTC

Market Talk

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20 paź 2025, 17:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 paź 2025, 17:01 UTC

Market Talk

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20 paź 2025, 16:43 UTC

Market Talk

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20 paź 2025, 16:25 UTC

Market Talk

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Peer Comparison

Price change

Relay Therapeutics Inc Forecast

Price Target

By TipRanks

111.25% upside

12 Months Forecast

Average 13.71 USD 111.25%

High 19 USD

Low 4 USD

Based on 9 Wall Street analysts offering 12 month price targets forRelay Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Relay Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

2.88 / 3.285Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

160 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.